MOLN Valuation

Molecular Partners AG

Add to Watchlist

Advanced Chart

3.670

-0.1(-2.653%)1D

Overview
Forecast
Valuation
Earnings

MOLN Relative Valuation

MOLN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, MOLN is overvalued; if below, it's undervalued.

Historical Valuation

Molecular Partners AG (MOLN) is now in the Fair zone, suggesting that its current forward PS ratio of 26.20 is considered Fairly compared with the five-year average of -3.77. The fair price of Molecular Partners AG (MOLN) is between 1.03 to 16.56 according to relative valuation methord.

Relative Value

Fair Zone

1.03-16.56

Current Price：3.67

Fair

-2.38

Trailing

Forward

0.16

EV/EBITDA

Molecular Partners AG. (MOLN) has a current EV/EBITDA of 0.16. The 5-year average EV/EBITDA is 6.51. The thresholds are as follows: Strongly Undervalued below -66.90, Undervalued between -66.90 and -30.19, Fairly Valued between 43.22 and -30.19, Overvalued between 43.22 and 79.92, and Strongly Overvalued above 79.92. The current Forward EV/EBITDA of 0.16 falls within the Historic Trend Line -Fairly Valued range.

0.12

EV/EBIT

Molecular Partners AG. (MOLN) has a current EV/EBIT of 0.12. The 5-year average EV/EBIT is -1.89. The thresholds are as follows: Strongly Undervalued below -15.53, Undervalued between -15.53 and -8.71, Fairly Valued between 4.94 and -8.71, Overvalued between 4.94 and 11.76, and Strongly Overvalued above 11.76. The current Forward EV/EBIT of 0.12 falls within the Historic Trend Line -Fairly Valued range.

26.20

Molecular Partners AG. (MOLN) has a current PS of 26.20. The 5-year average PS is 29.39. The thresholds are as follows: Strongly Undervalued below -55.76, Undervalued between -55.76 and -13.19, Fairly Valued between 71.97 and -13.19, Overvalued between 71.97 and 114.54, and Strongly Overvalued above 114.54. The current Forward PS of 26.20 falls within the Historic Trend Line -Fairly Valued range.

-3.03

P/OCF

Molecular Partners AG. (MOLN) has a current P/OCF of -3.03. The 5-year average P/OCF is -3.71. The thresholds are as follows: Strongly Undervalued below -22.43, Undervalued between -22.43 and -13.07, Fairly Valued between 5.65 and -13.07, Overvalued between 5.65 and 15.01, and Strongly Overvalued above 15.01. The current Forward P/OCF of -3.03 falls within the Historic Trend Line -Fairly Valued range.

-1.86

P/FCF

Molecular Partners AG. (MOLN) has a current P/FCF of -1.86. The 5-year average P/FCF is -2.08. The thresholds are as follows: Strongly Undervalued below -21.46, Undervalued between -21.46 and -11.77, Fairly Valued between 7.61 and -11.77, Overvalued between 7.61 and 17.29, and Strongly Overvalued above 17.29. The current Forward P/FCF of -1.86 falls within the Historic Trend Line -Fairly Valued range.

Molecular Partners AG (MOLN) has a current Price-to-Book (P/B) ratio of 1.02. Compared to its 3-year average P/B ratio of 0.89 , the current P/B ratio is approximately 14.70% higher. Relative to its 5-year average P/B ratio of 2.09, the current P/B ratio is about -51.23% higher. Molecular Partners AG (MOLN) has a Forward Free Cash Flow (FCF) yield of approximately -54.23%. Compared to its 3-year average FCF yield of -25.38%, the current FCF yield is approximately 113.67% lower. Relative to its 5-year average FCF yield of -13.56% , the current FCF yield is about 300.09% lower.

1.02

P/B

Median3y

0.89

Median5y

2.09

-54.23

FCF Yield

Median3y

-25.38

Median5y

-13.56

Competitors Valuation Multiple

The average P/S ratio for MOLN's competitors is 8.73, providing a benchmark for relative valuation. Molecular Partners AG Corp (MOLN) exhibits a P/S ratio of 26.20, which is 200.00% above the industry average. Given its robust revenue growth of -100.00%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

MOLN.O

Molecular Partners AG

Spero Therapeutics Inc

Armata Pharmaceuticals Inc

Loss

109.41M

FATE.O

Fate Therapeutics Inc

Zentalis Pharmaceuticals Inc

Loss

109.65M

Performance Decomposition

Market capitalization of MOLN increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of MOLN in the past 1 year is driven by Unknown.